Search results
Results From The WOW.Com Content Network
The COVID-19 vaccination program in the Philippines was a mass immunization campaign against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (COVID-19), in response to the pandemic in the country. The vaccination program was initiated by the Duterte administration on March 1, 2021, a ...
National regulatory authorities have granted full or emergency use authorizations for 40 COVID-19 vaccines.. Ten vaccines have been approved for emergency or full use by at least one stringent regulatory authority recognized by the World Health Organization (WHO): Pfizer–BioNTech, Oxford–AstraZeneca, Sinopharm BIBP, Moderna, Janssen, CoronaVac, Covaxin, Novavax, Convidecia, and Sanofi ...
The Sinopharm BIBP COVID-19 vaccine, also known as BBIBP-CorV, [2] the Sinopharm COVID-19 vaccine, [3] or BIBP vaccine, [3][4][5] is one of two whole inactivated virus COVID-19 vaccines developed by Sinopharm 's Beijing Institute of Biological Products (sometimes written as Beijing Bio-Institute of Biological Products, [6] resulting in the two ...
Philippines President Rodrigo Duterte received his first dose of Sinopharm's vaccine against COVID-19 on Monday to encourage reluctant Filipinos to get inoculated and help stop the spread of the ...
The Sinopharm WIBP COVID-19 vaccine, also known as WIBP-CorV, [ 2 ][ 3 ] is one of two inactivated virus COVID-19 vaccines developed by Sinopharm. Peer-reviewed results show that the vaccine is 72.8% effective against symptomatic cases and 100% against severe cases (26 cases in vaccinated group vs. 95 cases in placebo group). [ 4 ]
Sinopharm NVSI COVID-19 vaccine, also known as mutI-tri-RBD or NVSI-06-08, is a COVID-19 vaccine developed by National Vaccine & Serum Institute (NVSI, 中生研究院), a subsidiary of CNBG of Sinopharm. [2][3] They claim to be the world's first "second generation broadly protective" recombination protein subunit vaccine, i.e. by combining ...
China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise.The corporation was the indirect major shareholder of publicly traded companies Sinopharm Group (SEHK: 1099, via a 51–49 joint venture, Sinopharm Industrial Investment, with Fosun Pharmaceutical), China Traditional Chinese Medicine [] (SEHK: 570, mostly via ...
CoronaVac, also known as the Sinovac COVID-19 vaccine, [4] was a whole inactivated virus COVID-19 vaccine developed by the Chinese company Sinovac Biotech. [5][6] It was phase III clinically trialled in Brazil, [7] Chile, [8] Indonesia, [9] the Philippines, [10] and Turkey [11] and relies on traditional technology similar to other inactivated ...